Alx Oncology Holdings Inc (ALXO) Stock Price, Quote & News

Latest News on ALXO

Dec 18, 2024, 8:00 AM EST - 4 weeks ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Nov 14, 2024, 8:00 AM EST - 2 months ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 7, 2024, 4:00 PM EST - 2 months ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 1, 2024, 5:30 PM EDT - 2 months ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Sep 11, 2024, 10:36 PM EDT - 4 months ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Aug 6, 2024, 4:01 PM EDT - 5 months ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Jul 31, 2024, 4:01 PM EDT - 6 months ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 6 months ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 27, 2024, 4:13 AM EDT - 7 months ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 2, 2024, 10:00 AM EDT - 8 months ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024, 9:00 AM EDT - 8 months ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 9, 2024, 4:00 PM EDT - 9 months ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 9:00 AM EDT - 9 months ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Apr 24, 2024, 10:00 AM EDT - 9 months ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

$ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)$

Apr 9, 2024, 5:30 PM EDT - 10 months ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Mar 7, 2024, 4:03 PM EST - 11 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 11 months ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Dec 8, 2023, 8:30 AM EST - 1 year ago

ALX Oncology shares jump 9% after Jefferies upgrade

Nov 13, 2023, 4:05 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 10, 2023, 4:05 PM EDT - 1 year ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 9, 2023, 12:38 AM EDT - 1 year ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 5, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Announces Pricing of Public Offering

Oct 4, 2023, 4:10 PM EDT - 1 year ago

ALX Oncology Announces Proposed Public Offering

Oct 3, 2023, 6:00 AM EDT - 1 year ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Sep 6, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Realigns Executive Leadership Team

Aug 31, 2023, 7:00 AM EDT - 1 year ago

ALX Oncology Announces September Investor Conference Participation

Aug 10, 2023, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Jun 26, 2023, 7:00 AM EDT - 1 year ago

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

May 11, 2023, 4:01 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 9, 2023, 7:00 AM EDT - 1 year ago

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 13, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 9, 2023, 4:01 PM EST - 2 years ago

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

Feb 16, 2023, 7:00 AM EST - 2 years ago

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

Jan 5, 2023, 7:00 AM EST - 2 years ago

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

Jan 3, 2023, 7:00 AM EST - 2 years ago

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 10:00 AM EST - 2 years ago

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

Nov 29, 2022, 7:00 AM EST - 2 years ago

ALX Oncology Appoints Scott Garland to its Board of Directors

Nov 8, 2022, 4:01 PM EST - 2 years ago

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Nov 3, 2022, 9:00 AM EDT - 2 years ago

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

Nov 2, 2022, 7:00 AM EDT - 2 years ago

ALX Oncology Announces Upcoming Investor Conference Participation

Oct 31, 2022, 7:00 AM EDT - 2 years ago

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

Oct 5, 2022, 8:01 AM EDT - 2 years ago

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Sep 21, 2022, 4:01 PM EDT - 2 years ago

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Aug 16, 2022, 9:54 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

Aug 15, 2022, 7:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

Aug 11, 2022, 7:00 AM EDT - 2 years ago

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

Aug 8, 2022, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aug 1, 2022, 7:00 AM EDT - 2 years ago

Market Cap	85.97M
Revenue (ttm)	0.00
Net Income (ttm)	-160.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	579,700
Avg Vol	1,043,726
Day's Range	N/A - N/A
Shares Out	52.74M
Stochastic %K	47%
Beta	0.98
Analysts	Strong Sell
Price Target	$7.67